The Nitazoxanide Plus Atazanavir for COVID-19 Study

Covid-19 Clinical Trial

— NACOVID  

Official title:

A Randomized, Open Label Trial to Investigate the Efficacy and Safety of Nitazoxanide Plus Atazanavir/Ritonavir for the Treatment of COVID-19: a Pilot Study

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04459286
• Other study ID #: NACOVID
• Status: Terminated
• Phase: Phase 2
• Start date: October 9, 2020
• Est. completion date: May 2, 2021

Study information

• Verified date: February 2022
• Source: Obafemi Awolowo University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Since the outbreak of the novel coronavirus disease in 2019 (COVID-19), an unprecedented global search for potential therapeutics and vaccines is ongoing. In this study, a combination of two drugs that have been shown to be effective against the germ that causes COVID-19 in the laboratory will be tested in patients diagnosed with moderate to severe COVID-19. One of the drugs is called nitazoxanide and the second is atazanavir/ritonavir. Nitazoxanide has been used for the treatment of diarrhea since 2004 while atazanavir/ritonavir was approved for HIV treatment in 2003. They are known to be safe in humans.

In this pilot study, 98 COVID-19 patients will be recruited into two groups. The 49 patients in group 1 will receive the standard of care determined by their primary care providers while the 49 patients in group 2 will receive both the standard of care combined with the two study drugs. Patients in group 2 will receive the study drugs for 14 days and all patients will be monitored for a total of 28 days.

The time it takes for the germ that causes COVID-19 to be completely removed from the body (in nasal secretions) and the time to clinical improvement will be monitored in all patients and compared between the two groups.

Description:

COVID-19 caused by a novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) is an unprecedented global public health challenge which as at July 1, 2020 has spread to over 210 countries with over 10.6 million cases resulting in 514,808 deaths. More than 1500 clinical trials are currently ongoing in an unprecedented global search for potential therapeutics and vaccines. With increasing number of cases reported in low- and middle-income countries and and the possibility of a second wave of infections in countries where the pandemic appears to have slowed, studies to investigate promising therapies are urgently needed, especially those that can significantly reduce time to viral clearance and mortality. Shortening SARS-CoV-2 clearance time will lower treatment cost and reduce the economic impact of the pandemic.

The purpose of this phase 2 trial is to investigate the efficacy and safety of repurposed antiprotozoal and antiretroviral drugs, nitazoxanide and atazanavir/ritonavir, in achievement of SARS-CoV-2 PCR negativity and shorten the time to clinical improvement in patients diagnosed with moderate to severe COVID-19. The selection of candidates for this COVID-19 drug repurposing trial was guided by three pharmacological considerations: (1) demonstration of in-vitro anti-SARS-CoV-2 activity at doses shown or predicted to be tolerated by humans, (2) the feasibility of achieving effective concentration in relevant compartments, and (3) established human safety record.

This is a pilot phase 2, open label randomized controlled trial. A total of 98 patients with confirmed COVID-19 diagnosis (defined as SARS-CoV-2 polymerase chain reaction (PCR) positive nasopharyngeal swab) will be recruited from participating treatment centres. Participants will be randomised to receive either the standard of care (SOC) plus nitazoxanide for 14 days, starting from day 1 or the SOC alone for 14 days.

Participants will be recruited within 2 days of admission into COVID-19 treatment centre. Before enrollment, they will be given adequate information about the trial, opportunity to ask questions, and sufficient time to consider participation. Before any screening procedures, a written consent will be obtained from each eligible subject who agrees to participate in the trial. Participants will then be randomly allocated 1:1 to receive either the SOC alone (control group) or SOC plus study drug (intervention group). Parallel assignment will be used to prevent sample size imbalance between groups and control for important covariates (e.g. age, comorbidities, gender) that may affect trial results. Participants in the intervention group will receive 1000 mg nitazoxanide (two tablets of 500 mg each) with meal two times daily (8 am and 8 pm) and one tablet of 300/100 mg atazanavir/ritonavir with meal once daily (8 pm) in addition SOC. Participants in the control arm will receive the SOC alone. SOC will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19.

The treatment duration for participants in the intervention group will be 14 days. However, follow up will continue until day 28 after study entry at the end of which all participants will exit the study. Evaluations at follow up visits will include daily symptoms monitoring using inFLUenza Patient-Reported Outcome (FLU-PRO) questionnaire, daily vitals, daily clinical improvement assessment, and swab and/or sputum collection for SARS-CoV-2 on days 2, 4, 6, 7, 14, and 28.

Sample size estimation is based on the assumption that an improvement of at least 60-80% in time to SARS-CoV-2 PCR negativity and symptoms resolution can be achieved in the intervention group compared with the control group. Hence, a total sample size of 89 will provide at least 80% power to show or exclude 60% improvement in time to SARS-CoV-2 PCR negativity. This assumes a two-sided and 5% type 1 error rate. Therefore, providing for a 10% loss to follow up rate, a total of 98 patients will be recruited.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 57
• Est. completion date: May 2, 2021
• Est. primary completion date: May 2, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Willingness and ability to provide written informed consent

• At least 18 and not more than 75 years of age at study entry

• SARS-CoV-2 infection confirmed by PCR test within 4 days before randomization

• Currently symptomatic (fever or chills, cough, myalgia, sore throat, shortness of breath, or new onset of anosmia or ageusia) and at COVID-19 isolation and treatment centre

Exclusion Criteria:

• Inability to take orally administered medication or food

• Known hypersensitivity to study medication

• Pregnant or lactating (unless practicing exclusive replacement feeding for the entire study duration)

• Participation in any other interventional trial for COVID-19 (observational study co-enrollment allowed)

• Concurrent treatment with other agents with actual or possible direct-acting antiviral activity against SARS-CoV-2 less than 24 hours prior to study drug dosing

• Concurrent use of agents with known or uncertain interaction with study drugs, including ritonavir

• Requiring mechanical ventilation at screening

• Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) above 5 times upper limit of normal (ULN)

• Creatinine clearance below 50 mL/min using the Cockcroft-Gault formula for participants above 18 years of age

Related Conditions & MeSH terms

• Covid-19

Intervention

Drug:
• Nitazoxanide and atazanavir/ritonavir
1000 mg nitazoxanide tablets twice daily and 300/100 mg atazanavir/ritonavir tablets once daily with meal

Other:
• Standard of Care
SOC will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19

Locations

Country	Name	City	State
Nigeria	Infectious Disease Hospital, Olodo	Ibadan	Oyo State
Nigeria	Olabisi Onabanjo University Teaching Hospital	Sagamu	Ogun State

Sponsors (7)

Lead Sponsor	Collaborator
Obafemi Awolowo University	African Centre of Excellence for Genomics of Infectious Diseases, Infectious Disease Hospital Olodo, Obafemi Awolowo University Teaching Hospitals Complex, Olabisi Onabanjo University Teaching Hospital, Osun State Ministry of Health, University of Liverpool

Country where clinical trial is conducted

Nigeria, 

References & Publications (5)

Arshad U, Pertinez H, Box H, Tatham L, Rajoli RKR, Curley P, Neary M, Sharp J, Liptrott NJ, Valentijn A, David C, Rannard SP, O'Neill PM, Aljayyoussi G, Pennington SH, Ward SA, Hill A, Back DJ, Khoo SH, Bray PG, Biagini GA, Owen A. Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics. Clin Pharmacol Ther. 2020 Oct;108(4):775-790. doi: 10.1002/cpt.1909. Epub 2020 Jun 14. Review. Erratum in: Clin Pharmacol Ther. 2021 May;109(5):1362. — View Citation

Cao J, Forrest JC, Zhang X. A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs. Antiviral Res. 2015 Feb;114:1-10. doi: 10.1016/j.antiviral.2014.11.010. Epub 2014 Nov 28. — View Citation

Haffizulla J, Hartman A, Hoppers M, Resnick H, Samudrala S, Ginocchio C, Bardin M, Rossignol JF; US Nitazoxanide Influenza Clinical Study Group. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis. 2014 Jul;14(7):609-18. doi: 10.1016/S1473-3099(14)70717-0. Epub 2014 May 19. — View Citation

Rajoli RK, Pertinez H, Arshad U, Box H, Tatham L, Curley P, Neary M, Sharp J, Liptrott NJ, Valentijn A, David C, Rannard SP, Aljayyoussi G, Pennington SH, Hill A, Boffito M, Ward SA, Khoo SH, Bray PG, O'Neill PM, Hong WD, Biagini G, Owen A. Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis. medRxiv. 2020 May 6. pii: 2020.05.01.20087130. doi: 10.1101/2020.05.01.20087130. Update in: Br J Clin Pharmacol. 2020 Oct 21;:. — View Citation

Rossignol JF. Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. J Infect Public Health. 2016 May-Jun;9(3):227-30. doi: 10.1016/j.jiph.2016.04.001. Epub 2016 Apr 16. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to clinical improvement	Proportion of patients with clinical improvement, as defined by live discharge from the hospital, a decrease of at least 2 points from baseline on a 7-point ordinal scale, or both.	28 days
Primary	Time to SARS-CoV-2 negativity	Proportion of participants with SARS-CoV-2 polymerase chain reaction (PCR) negative result at Days 7, 10, 14 and 28	28 days
Primary	Difference in SARS-CoV-2 AUC	Temporal patterns of SARS-CoV-2 viral load quantified by RT-PCR from nasal swabs or sputum of patients receiving SOC alone versus SOC plus study drug	28 days
Secondary	Time to symptoms resolution	Time to symptoms resolution as monitored by the Performance of the inFLUenza Patient-Reported Outcome (FLU-PRO) questionnaire with some modifications for COVID-19	28 days
Secondary	Clinical status as assessed with the seven-category ordinal scale on days 7 and 14		14 days
Secondary	Duration of hospitalization in survivors		28 days
Secondary	Day 28 mortality		28 days
Secondary	Time from treatment initiation to death		28 days
Secondary	Proportion with viral RNA detection over time		28 days

External Links

•   Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production
•   Atazanavir/ritonavir Prescribing Information
•   Nitaxoxanide Prescribing Information